Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.

Four SD, Maenhout SK, Niclou SP, Thielemans K, Neyns B, Aerts JL. Am J Cancer Res. 2016 Nov 1;6(11):2514-2531. eCollection 2016.

The angiogenic switch leads to a metabolic shift in human glioblastoma

Talasila KM, Røsland GV, Hagland HR, Eskilsson E, Flønes IH, Fritah S, Azuaje F, Atai N, Harter PN, Mittelbronn M, Andersen M, Joseph JV, Hossain JA, Vallar L, Noorden CJ, Niclou SP, Thorsen F, Tronstad KJ, Tzoulis C, Bjerkvig R, Miletic H - Neuro Oncol. 2016 Sep 3. pii: now175. [Epub ahead of print]

LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer

Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt, Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y - EMBO Mol Med. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198.

DNA repair mechanisms and their clinical impact in glioblastoma

Erasimus H, Gobin M, Niclou SP, Van Dyck E - 2016 Jun. Mutat Res Rev Mutat Res.769:19-35.

Computational models for predicting drug responses in cancer research

Azuaje F - Brief Bioinform.2016 Jul 21. pii: bbw065. [Epub ahead of print]

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H - 2016 Jun. Neuro Oncol. [Epub ahead of print].

Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells.

Podergajs N, Motaln H, Rajcevic U, Verbovsek U, Korsic M, Obad N, Espedal H, Vittori M, Herold-Mende C, Miletic H, Bjerkvig R, Turnsek TL. Oncotarget. 2016 Jan 5;7(1):593-609. doi: 10.18632/oncotarget.5477.

Analysis of the dynamic co-expression network of heart regeneration in the zebrafish

Rodius S, Androsova G, Götz L, Liechti R, Crespo I, Merz S, Nazarov PV, de Klein N, Jeanty C, González-Rosa JM, Muller A, Bernardin F, Niclou SP, Vallar L, Mercader N, Ibberson M, Xenarios I, Azuaje F - 2016 May. Sci Rep.6:26822.

Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NHC, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R, Niclou SP. Oncotarget. 2016. [Epub ahead of print].

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)

Demeure K, Fack F, Duriez E, Tiemann K, Bernard A, Golebiewska A, Bougnaud S, Bjerkvig R, Domon B, Niclou SP - 2016 Feb. Mol Cell Proteomics.15(2):481-92. Epub 2015 Aug 4.

Transcriptomic analyses of primary astrocytes under TNFα treatment

Birck C, Koncina E, Heurtaux T, Glaab E, Michelucci A, Heuschling P, Grandbarbe L.  Genom Data. 2016;7:7-11

Experimental therapies: gene therapies and oncolytic viruses.

Hulou MM, Cho CF, Chiocca EA, Bjerkvig R. Handb Clin Neurol. 2016;134:183-97.

CRP2, a new invadopodia actin bundling factor critically promotes breast cancer cell invasion and metastasis.

Hoffmann C, Mao X, Dieterle M, Moreau F, Al Absi A, Steinmetz A, Oudin A, Berchem G, Janji B, Thomas C. Oncotarget. 2016. [Epub ahead of print].

Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism.

Meiser J, Delcambre S, Wegner A, Jager C, Ghelfi J, D'Herouel AF, Dong X, Weindl D, Stautner C, Nonnenmacher Y, Michelucci A, Popp O, Giesert F, Schildknecht S, Kramer L, Schneider JG, Woitalla D, Wurst W, Skupin A, Weisenhorn DM, Kruger R, Leist M, Hiller K. Neurobiol Dis. 2016. [Epub ahead of print].

Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition.

Herkert B, Kauffmann A, Molle S, Schnell C, Ferrat T, Voshol H, Juengert J, Erasimus H, Marszalek G, Kazic-Legueux M, Billy E, Ruddy DA, Stump MD, Guthy D, Ristov M, Calkins K, Maira SM, Sellers WR, Hofmann F, Hall M, Brachmann SM. - Cancer Res.2016 Jan 15;76(2):390-402. doi: 10.1158/0008-5472.CAN-14-3358. Epub 2015 Nov 17.